Treatment with the cell therapy Descartes-08 led to long-term reductions in symptom severity for people with myasthenia gravis (MG) taking part in a Phase 2b clinical trial, according to updated data announced by therapy developer Cartesian Therapeutics. “Participants dosed with a single six-week course of treatment of…
News
Epysqli (eculizumab-aagh), a biosimilar of Soliris (eculizumab), is now available in the U.S. to treat adults with generalized myasthenia gravis (gMG) who test positive for antibodies against acetylcholine receptors (AChRs), the most common type of MG-causing antibodies. Besides myasthenia gravis (MG), Epysqli will also be available for…
Problems speaking and swallowing are common among people with myasthenia gravis (MG), but speech-language evaluations and treatment are not carried out as part of routine care for MG patients, a new study by a trio of U.S. researchers has found. Indeed, compared with the general population, individuals with MG…
Scientists in Korea have developed a cell-based test that can be used to detect antibodies against agrin, a protein involved in nerve-muscle communication that is sometimes targeted by harmful autoantibodies in people with myasthenia gravis (MG). The researchers said they validated the test “and have demonstrated that this [cell-based…
UCB’s injection therapy Rystiggo (rozanolixizumab-noli) has been granted regulatory approval in Canada for adults with generalized myasthenia gravis (gMG) who test positive for antibodies against the acetylcholine receptor (AChR) or muscle-specific tyrosine kinase (MuSK) proteins. Anti-AChR or anti-MuSK antibodies — self-reactive antibodies that target the body’s own healthy…
More than 500 members of the myasthenia gravis (MG) community are expected at a conference featuring strategies for patient education, advances in science and treatment, and discussions on managing MG. The Myasthenia Gravis Foundation of America (MGFA)’s National Patient Conference, being held March 30-April 1 in Phoenix and virtually, is…
Myasthenia gravis (MG) is associated with a high personal and societal economic burden, due to work engagement and income difficulties, physician visits, hospitalizations, and medications. That’s according to a new study from Germany that analyzed responses from patient surveys on personal burden, as well as data from a claims…
Investigational therapy batoclimab eased disease severity for adults with generalized myasthenia gravis (gMG) in a Phase 3 trial, but the treatment’s developer said it’s not planning to seek regulatory approval of the treatment for gMG in the U.S. Immunovant, a Roivant subsidiary, is instead focused on using the…
A digital tool developed by BioSensics for remotely monitoring myasthenia gravis (MG) symptoms was found to be feasible in a small clinical study. BioDigit MG includes various assessments that can be completed on a tablet, along with wearable sensors to collect information about physical activity and posture…
One year of treatment with inebilizumab eased symptoms and improved daily functioning for people with generalized myasthenia gravis (gMG) positive for antibodies against the acetylcholine receptor (AChR), according to new data from the Phase 3 MINT clinical trial. Amgen, the company developing inebilizumab, will present the new…
Recent Posts
- My twin loves junk food, but a veggie and fruit diet is helping him combat MG
- My secret book of survival in life with myasthenia gravis
- MG symptoms in US strike earlier and harder depending on race and ethnicity
- FDA grants priority review for expanded Vyvgart use in gMG
- Swallowing issues highly common in MG patients: Study review